Glucose metabolism and pancreatic defects in spinal muscular atrophy

Annals of Neurology

Volumn 72, Issue 2, 2012, Pages 256-268

  Bowerman, Melissa ^a,b   Swoboda, Kathryn J ^c   Michalski, John Paul ^a,b   Wang, Gen Sheng ^a   Reeks, Courtney ^d   Beauvais, Ariane ^a   Murphy, Kelley ^c   Woulfe, John ^a,b   Screaton, Robert A ^b,d   Scott, Fraser W ^a,b   Kothary, Rashmi ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FATE; CONTROLLED STUDY; DISEASE SEVERITY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MOUSE; NONHUMAN; PANCREAS DISEASE; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SPINAL MUSCULAR ATROPHY;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BLOOD GLUCOSE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GLUCAGON; GLUCOSE METABOLISM DISORDERS; HUMANS; IN SITU NICK-END LABELING; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PANCREATIC DISEASES; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD; SURVIVAL OF MOTOR NEURON 1 PROTEIN;

EID: 84865592642     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23582     Document Type: Article

References (53)

1. Pearn J,. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978; 15: 409-413. (Pubitemid 9093440)
2. Crawford TO, Pardo CA,. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 1996; 3: 97-110. (Pubitemid 26275339)
3. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155-165.
4. Jablonka S, Schrank B, Kralewski M, et al. Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. Hum Mol Genet 2000; 9: 341-346. (Pubitemid 30098726)
5. Lorson CL, Hahnen E, Androphy EJ, Wirth B,. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 1999; 96: 6307-6311. (Pubitemid 29256661)
6. Kashima T, Manley JL,. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet 2003; 34: 460-463. (Pubitemid 36935342)
7. Cartegni L, Krainer AR,. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002; 30: 377-384.
8. Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997; 16: 265-269. (Pubitemid 27280210)
9. Walker MP, Rajendra TK, Saieva L, et al. SMN complex localizes to the sarcomeric Z-disc and is a proteolytic target of calpain. Hum Mol Genet 2008; 17: 3399-3410.
10. Murray LM, Comley LH, Thomson D, et al. Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet 2008; 17: 949-962. (Pubitemid 351426029)
11. Heier CR, Satta R, Lutz C, DiDonato CJ,. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet 2010; 19: 3906-3918.
12. Shababi M, Habibi J, Yang HT, et al. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet 2010; 19: 4059-4071.
13. Bevan AK, Hutchinson KR, Foust KD, et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet 2010; 19: 3895-3905.
14. Bowerman M, Anderson CL, Beauvais A, et al. SMN, profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis. Mol Cell Neurosci 2009; 42: 66-74.
15. DiDonato CJ, Lorson CL, De Repentigny Y, et al. Regulation of murine survival motor neuron (Smn) protein levels by modifying Smn exon 7 splicing. Hum Mol Genet 2001; 10: 2727-2736. (Pubitemid 33133414)
16. Schrank B, Gotz R, Gunnersen JM, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A 1997; 94: 9920-9925. (Pubitemid 27408166)
17. Heikkinen S, Argmann CA, Champy MF, Auwerx J,. Evaluation of glucose homeostasis. Curr Protoc Mol Biol 2007;Chapter 29:Unit 29B.3.
18. Fu A, Ng AC, Depatie C, et al. Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab 2009; 10: 285-295.
19. Crawford TO, Sladky JT, Hurko O, et al. Abnormal fatty acid metabolism in childhood spinal muscular atrophy. Ann Neurol 1999; 45: 337-343. (Pubitemid 29120038)
20. Quarfordt SH, DeVivo DC, Engel WK, et al. Familial adult-onset proximal spinal muscular atrophy. Report of a family with type II hyperlipoproteinemia. Arch Neurol 1970; 22: 541-549.
21. Dahl DS, Peters HA,. Lipid disturbances associated with spiral muscular atrophy. Clinical, electromyographic, histochemical, and lipid studies. Arch Neurol 1975; 32: 195-203.
22. Tein I, Sloane AE, Donner EJ, et al. Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)? Pediatr Neurol 1995; 12: 21-30.
23. Bowerman M, Beauvais A, Anderson CL, Kothary R,. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum Mol Genet 2010; 19: 1468-1478.
24. Butchbach ME, Rose FF Jr, Rhoades S, et al. Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem Biophys Res Commun 2010; 391: 835-840.
25. Bowerman M, Murray LM, Beauvais A, et al. A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. Neuromuscul Disord 2012; 22: 263-276.
26. Taniguchi CM, Emanuelli B, Kahn CR,. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96. (Pubitemid 43278292)
27. Shanik MH, Xu Y, Skrha J, et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008; 31 (suppl 2): S262-S268.
28. Rojas A, Khoo A, Tejedo JR, et al. Islet cell development. Adv Exp Med Biol 2010; 654: 59-75.
29. Bosco D, Armanet M, Morel P, et al. Unique arrangement of alpha- and beta-cells in human islets of Langerhans. Diabetes 2010; 59: 1202-1210.
30. Cabrera O, Berman DM, Kenyon NS, et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A 2006; 103: 2334-2339. (Pubitemid 43271670)
31. Dodart JC, Mathis C, Bales KR, et al. Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Neurosci Lett 1999; 277: 49-52.
32. de la Monte SM, Wands JR,. Alzheimer's disease is type 3 diabetesâevidence reviewed. J Diabetes Sci Technol 2008; 2: 1101-1113.
33. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ,. Prader-Willi syndrome. Genet Med 2012; 14: 10-26.
34. Stefan M, Simmons RA, Bertera S, et al. Global deficits in development, function, and gene expression in the endocrine pancreas in a deletion mouse model of Prader-Willi syndrome. Am J Physiol Endocrinol Metab 2011; 300: E909-E922.
35. Yan H, Gu W, Yang J, et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther 2009; 329: 102-111.
36. Liu Z, Kim W, Chen Z, et al. Insulin and glucagon regulate pancreatic alpha-cell proliferation. PLoS One 2011; 6: e16096.
37. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47: 358-364. (Pubitemid 28104196)
38. Kim A, Miller K, Jo J, et al. Islet architecture: a comparative study. Islets 2009; 1: 129-136.
39. Zochodne DW, Ramji N, Toth C,. Neuronal targeting in diabetes mellitus: a story of sensory neurons and motor neurons. Neuroscientist 2008; 14: 311-318. (Pubitemid 352010065)
40. Ramji N, Toth C, Kennedy J, Zochodne DW,. Does diabetes mellitus target motor neurons? Neurobiol Dis 2007; 26: 301-311. (Pubitemid 46561334)
41. Huang S, Czech MP,. The GLUT4 glucose transporter. Cell Metab 2007; 5: 237-252. (Pubitemid 46477860)
42. Sinnreich M, Sorenson EJ, Klein CJ,. Neurologic course, endocrine dysfunction and triplet repeat size in spinal bulbar muscular atrophy. Can J Neurol Sci 2004; 31: 378-382. (Pubitemid 39295458)
43. Barris RW,. Hyperinsulinism and neuromuscular disorders; a consideration of the association of pancreatic adenoma with wasting states. Calif Med 1953; 78: 224-226.
44. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 2010; 107: 7036-7041.
45. Di Cola G, Cool MH, Accili D,. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 1997; 99: 2538-2544. (Pubitemid 27227733)
46. Ranke MB,. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab 2005; 16: 190-197. (Pubitemid 40603099)
47. Bosch-Marce M, Wee CD, Martinez TL, et al. Increased IGF-1 in muscle modulates the phenotype of severe SMA mice. Hum Mol Genet 2011; 20: 1844-1853.
48. Stiles BL, Kuralwalla-Martinez C, Guo W, et al. Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 2006; 26: 2772-2781.
49. Ning K, Drepper C, Valori CF, et al. PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons. Hum Mol Genet 2010; 19: 3159-3168.
50. Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007; 117: 659-671. (Pubitemid 46348524)
51. Sun C, Zhou J,. Trichostatin A improves insulin stimulated glucose utilization and insulin signaling transduction through the repression of HDAC2. Biochem Pharmacol 2008; 76: 120-127.
52. Narver HL, Kong L, Burnett BG, et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann Neurol 2008; 64: 465-470.
53. Rivellese AA, De Natale C, Lilli S,. Type of dietary fat and insulin resistance. Ann N Y Acad Sci 2002; 967: 329-335. (Pubitemid 34721918)